Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on September 22, 2021. The registrant is a Delaware corporation headquartered in Cambridge, MA, and is classified as an emerging growth company. The report details the entry into a material definitive agreement regarding a public offering of securities.
Key Financial Metrics and Transaction Details
The filing discloses the terms of an underwritten public offering rather than historical financial performance metrics such as revenue or profit.
- Securities Issued: 22,828,072 shares of Common Stock and pre-funded warrants to purchase 8,771,928 shares of Common Stock.
- Offering Price: $2.85 per share of Common Stock; $2.849 per pre-funded warrant.
- Gross Proceeds: Approximately $90 million (excluding underwriting discounts, commissions, and expenses).
- Underwriters' Option: An option to purchase up to an additional 4,740,000 shares of Common Stock at $2.85 per share, exercisable for 30 days.
- Expected Closing Date: September 24, 2021.
Material Changes and Use of Proceeds
The primary material change is the execution of the Underwriting Agreement with Piper Sandler & Co. and Raymond James & Associates, Inc. The filing does not provide comparative financial data against prior periods. The Company intends to use the net proceeds for:
- Continued development of DKN-01.
- Manufacturing of clinical trial material.
- General corporate purposes, including working capital and general and administrative expenses.
Guidance, Risks, and Unusual Items
Lock-Up Agreements: Certain officers and directors agreed not to sell or dispose of Common Stock for 90 days following the date of the final prospectus supplement, subject to exceptions and written consent from Piper Sandler & Co.
Pre-Funded Warrants: These instruments have an exercise price of $0.001 per share. They do not carry voting rights or other privileges of Common Stock holders until exercised. They are subject to adjustment for stock splits, dividends, or similar events.
Risks and Contingencies: The transaction is subject to customary closing conditions. The summary of the Underwriting Agreement is qualified by the full agreement and confidential disclosures exchanged between parties.
Investor Verification Checklist
- Verify the final closing of the offering on or around September 24, 2021.
- Confirm the exercise of the Underwriters' Option for the additional 4,740,000 shares.
- Review the final prospectus supplement (Rule 424(b)) for updated terms and risk factors.
- Monitor the Company's cash burn rate and progress on the DKN-01 clinical development program.
- Check for any subsequent filings regarding the lock-up expiration for officers and directors.